Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
36.36
+0.08 (0.22%)
At close: Jul 24, 2026, 4:00 PM EDT
37.36
+1.00 (2.75%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Agios Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $42.63. The average 1-year stock price forecast is 17.24% higher than the current stock price, while the lowest is $31 (-14.74%) and the highest is $59 (+62.27%).
Price Target: $42.63 (+17.24%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $46 | Buy | Maintains | $46 | +26.51% | Jul 22, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $54 → $52 | Buy | Maintains | $54 → $52 | +43.01% | Jul 21, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 7, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $28 → $32 | Hold | Maintains | $28 → $32 | -11.99% | Jul 7, 2026 |
Financial Forecast
Revenue This Year
120.40M
from 54.03M
Increased by 122.85%
Revenue Next Year
263.22M
from 120.40M
Increased by 118.62%
EPS This Year
-6.21
from -7.12
EPS Next Year
-4.56
from -6.21
EPS and Forward PE are based on non-GAAP adjusted numbers.